|
Alemtuzumab for multiple screrosis |
Alva Diaz C, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alva Diaz C, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L. Alemtuzumab for multiple screrosis. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Documentos de Evaluación de Tecnologías Sanitarias, Informe de Respuesta Rápida N° 462. 2016 Authors' conclusions The evidence found on alemtuzumab for multiple sclerosis is scarce and of high quality. In direct comparisons, an increased effectiveness was observed for alemtuzumab versus interferon beta 1-alpha in decreasing relapses and disability increase in patients with relapsing-remitting multiple sclerosis, although with higher rates of significant adverse effects. There are no direct comparisons with other alternative drugs. The United States Food and Drug Administration, the European Drug Agency, different coverage policies and clinical practice guidelines approve and/or recommend its use for patients with highly active relapsing-remitting multiple sclerosis and/or highly refractory to other drugs.
The Latin-American health sponsors do not cover it, being its high cost its main limitation for indication; its choice over other available options (fingolimod, teriflunomide, etc), will depend on the severity and the refractoriness, the presence of contraindications and the patient's preferences.
Final publication URL www.iecs.org.ar Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Humanized; Humans; Multiple Sclerosis, Relapsing-Remitting Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32016000909 Date abstract record published 03/08/2016 |
|
|
|